Brian Raven, chief executive of PLC () runs through their results for the year to the end of March 2017.
Turnover was up 22% at £36.4mln giving EBITDA of £537,000, up 421%.
Cash generation was £497,000 in the second half.
The company saw its net assets more than double to £18.2mln in the period, while funds under management were ahead 332% at £769mln.
Meet Alliance Pharma PLC, IXICO PLC, Benchmark Holdings PLC, Clinigen Group PLC and Shield Therapeutics PLC at our event,
London , 24 January 2019.
Register here »